TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04135651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paratracheal pressure
Description: To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cricoid pressure
Description: To apply cricoid pressure, the crocoid cartilage was compressed with a single-handed three-finger maneuvre towards the vertebral bodies.
Study: NCT00221325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraventricular Rituximab Plus MTX
Description: Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.~First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.~If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.~Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing.
Study: NCT02755090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Saline
Study: NCT02196545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT00727337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LACE-computer
Description: Computerized Auditory Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PLACEBO-Directed listening
Description: Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lace-DVD
Description: DVD based Auditory Training
Study: NCT02162433

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: to arms 2,4. Serves as the placebo.
Study: NCT01557972

Intervention type: PROCEDURE
Intervention: Blood pressure measurement based on HBP or CBP
Description: To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
Study: NCT02708511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64-DOTA B-Fab
Description: Given IV
Study: NCT02162433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: to arms 1,3
Study: NCT01557972

Intervention type: PROCEDURE
Intervention: Blood pressure measurement based on HBP or CBP
Description: To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
Study: NCT02708511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02054195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
Study: NCT01208415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular repair for aortoiliac or iliac aneurysms.
Description: Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
Study: NCT02930642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition DVD
Description: Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
Study: NCT02054195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Training
Description: Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
Study: NCT01139372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 115958D (Lubricant Eye Drop)
Description: 1 drop in each eye at least twice daily
Study: NCT03657264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277 0.1 mmol/kg
Description: Single intravenous bolus injection at 2 mL/sec
Study: NCT02708511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03657264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277 0.1 mmol/kg
Description: Single intravenous bolus injection at 2 mL/sec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277 0.1 mmol/kg
Description: Single intravenous bolus injection at 2 mL/sec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277 0.1 mmol/kg
Description: Single intravenous bolus injection at 2 mL/sec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: One tablet per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: One tablet per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: One tablet per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: One tablet per os
Study: NCT02708511

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT00233571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneous (SC) every other week (EOW)
Study: NCT02424487

Intervention type: PROCEDURE
Intervention: Intracuff pressure measurement in one-lung ventilation during thoracic surgery
Study: NCT03155451

Intervention type: DIAGNOSTIC_TEST
Intervention: methylation markers screening
Description: ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
Study: NCT04642664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib plus Camrelizumab
Description: Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
Study: NCT00500071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse (lisdexamfetamine dimesylate)
Description: Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
Study: NCT01519726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT02355340

Intervention type: OTHER
Intervention: Dual energy x-ray absorptiometry (DXA)
Description: Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.

Intervention type: OTHER
Intervention: Peripheral quantitative computed tomography (pQCT)
Description: Subjects will undergo pQCT assessment of radius and tibia.
Study: NCT03657264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 0.9%
Description: Single intravenous bolus injection at 2 mL/sec
Study: NCT04510259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Brachial plexus Block
Description: It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1: 200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
Study: NCT03657264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 0.9%
Description: Single intravenous bolus injection at 2 mL/sec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 0.9%
Description: Single intravenous bolus injection at 2 mL/sec
Study: NCT01277575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rtACS stimulation (Verum condition)
Description: Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo condition
Description: A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
Study: NCT01370070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: 200mg weekly repeated q 28 days
Study: NCT03004560

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscopic Approach
Description: Minimally invasive laparoscopic surgery with 5-10 mm incisions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Approach
Description: Minimally invasive laparoscopic surgery with 2-3 mm incisions.
Study: NCT00520598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V505 formulation 1
Description: 0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: V505 formulation 2
Description: 0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: V505 formulation 2
Description: 0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V505 formulation 3
Description: 0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant
Description: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (unspecified)
Description: 0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (unspecified)
Description: 0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
Study: NCT03289715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On Demand Humidification system Mark 2
Description: The on demand humidification humidifier is set up to alternate between periods of humidification and no humidification totaling 6 periods of 30 minutes duration each. Thus, the test will consist of 3 cycles of disabled humidification and enabled humidification. Each cycle will be with a different humidification setting to assess which setting is most comfortable. In the second phase, the patient will be treated with the dose they had the best experience with in the first test.
Study: NCT01767233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP and pancreatic stenting
Study: NCT04421651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy group
Description: DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks.
Study: NCT02048514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Nellix® EndoVascular Aneurysm Sealing System
Study: NCT02612597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bedrest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Study: NCT03444025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.
Study: NCT03629509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEFORE decision aid
Description: Implementation of the BEFORE decision aid in clinical practice

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BEFORE decision aid
Description: Implementation of the BEFORE decision aid on RUBY communication portals

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BEFORE decision aid
Description: Review impact of BEFORE decision aid implementation in clinical practice
Study: NCT03614390

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mindfulness based cognitive therapy (MBCT)
Description: a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
Study: NCT04231981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA0012
Description: INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
Study: NCT01343615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid stenting
Description: A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy
Description: A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
Study: NCT04543448

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Rehabilitation for multiple sclerosis
Description: Traditional rehabilitation program include strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical mobilization for multiple sclerosis
Description: Cervical mobilization program include myofascial relaxation techniques and mobilization to cervical spine in addition to traditional program.
Study: NCT03657264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 0.9%
Description: Single intravenous bolus injection at 2 mL/sec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277 0.3 mmol/kg
Description: Single intravenous bolus injection at 2 mL/sec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277 0.3 mmol/kg
Description: Single intravenous bolus injection at 2 mL/sec
Study: NCT02418494

Intervention type: OTHER
Intervention: Concept Elicitation
Description: Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
Study: NCT03657264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277 0.3 mmol/kg
Description: Single intravenous bolus injection at 2 mL/sec
Study: NCT02418494

Intervention type: OTHER
Intervention: Comprehension Assessment
Description: Comprehension assessment of draft quality of life assessment
Study: NCT02835495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELP Vets Intervention
Description: This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
Study: NCT02473887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron with1:1 ORA - sweet.
Description: single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
Study: NCT01350622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PENNSAID
Description: active treatment with PENNSAID and oral placebo. Subjects will apply 40 drops of Pennsaid to the affected ankle joint once, and will take a single placebo pill.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac hydroxyethylpyrrolidine
Description: active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
Study: NCT04454905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is a novel angiogenesis inhibitor vascular endothelial growth factor 2.
Study: NCT02411591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV.
Study: NCT00901498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
Study: NCT02835495

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Education Program
Description: Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
Study: NCT00609609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photopheresis
Description: 8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
Study: NCT03767374

Intervention type: PROCEDURE
Intervention: Inguinal swab sample
Description: Inguinal samples using swab at cross-sectional visit

Intervention type: PROCEDURE
Intervention: Inguinal swab sample
Description: Inguinal samples using swab at cross-sectional visit
Study: NCT00901498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
Study: NCT03336866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXT-m200
Description: IXT-m200 is an anti-methamphetamine monoclonal antibody
Study: NCT03290729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wedge shape implants insertion
Description: Narrow dental implants inserted in narrow ridges
Study: NCT00609609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
Study: NCT01243424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: linagliptin tablets 5mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride over-encapsulated tablet 1-4 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin placebo
Description: linagliptin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride placebo
Description: glimepiride placebo
Study: NCT02612467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratified care
Description: Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current care
Description: Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.